Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
07/19/2017 07/20/2017 07/21/2017 07/24/2017 07/25/2017 Date
5.9 5.87 5.84 5.81 5.82 Last
1655 825 350 9852 400 Volume
-0.67% -0.51% -0.51% -0.51% +0.17% Change
Financials ( CAD)
Sales 2017 38,9 M
EBIT 2017 -22,3 M
Net income 2017 -29,0 M
Debt 2017 -
Yield 2017 -
Sales 2018 61,5 M
EBIT 2018 2,89 M
Net income 2018 -7,68 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 4,78x
Capi. / Sales2018 3,02x
Capitalization 186 M
More Financials
Company
Cardiome Pharma Corp. is a pharmaceutical company engages in provision of development and commercialization of medical products.It focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.It offers the Brinavess and Aggrastat... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on CARDIOME PHARMA CORP
07/05 CARDIOME PHARMA : Announces Licensing Agreement for XYDALBA™ (Dalbavancin ..
07/05 CARDIOME PHARMA : Announces Voting Results
07/04 CARDIOME PHARMA : Partner SteadyMed Submits U.S. New Drug Application for TREVYE..
07/03 CARDIOME PHARMA : Partner SteadyMed Submits U.S. New Drug Application for TREVYE..
06/23 CARDIOME PHARMA CORP. : Announces Voting Results
06/21 CARDIOME PHARMA : Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hyd..
05/16 CARDIOME PHARMA : Reports Changes To Senior Management Team
05/15 CARDIOME PHARMA : Reports First Quarter 2017 Financial Results
05/15 CARDIOME PHARMA CORP : Investor Network: Cardiome Pharma Corp. to Host Earnings ..
05/15 CARDIOME PHARMA : Announces Amendment to Term Loan Agreement with CRG-Managed Fu..
More news
Sector news : Biopharmaceuticals
07/25DJGlaxoSmithKline Names Former Wal-Mart Executive as Chief Digital and Technolo..
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/25DJABBVIE : Jury Backs AbbVie Payment -- WSJ
07/25DJSamsung Enters U.S. Drug Market -- WSJ
07/24DJABBVIE : Ordered to Pay $150 Million in AndroGel Lawsuit
More sector news : Biopharmaceuticals
News from SeekingAlpha
07/17 Canadian regulator OK's high-dose bolus regimen of Cardiome's Aggrastat
07/17 Premarket analyst action - healthcare
06/21 Cardiome inks distribution deal in Israel for antibiotic Xydalba; shares ahea..
06/19 FDA OKs new antibiotic to fight ABSSSI
06/12 Cardiome launches Brinavess in Canada
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,7  CAD
Spread / Average Target 85%
EPS Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Justin A. Renz Chief Financial Officer
Richard M. Glickman Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP46.97%148
BIOGEN8.27%60 389
CSL LIMITED25.50%45 154
ALEXION PHARMACEUTICALS5.72%29 359
GRIFOLS SA20.55%16 816
BIOMARIN PHARMACEUTICAL6.99%15 706